Revumenib

NEW YORK 纽约, ，June 04, 2026 (GLOBE NEWSWIRE) -- （环球电讯社）——Syndax Pharmaceuticals, Inc. Syndax制药公司(“Syndax”) (NASDAQ: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered into privately negotiated subscription agreements for the issuance of （“Syndax”）（纳斯达克股票代码：SNDX），一家致力于推进创新癌症疗法的商业化阶段生物制药公司，已就发行事宜达成私下协商的认购协议$250.0 million 2.5亿美元aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (the “Notes”). The sale of the Notes is expected to close on 2031年到期的2.25%可转换高级票据（“票据”）的本金总额。票据的出售预计将于June 10, 2026 2026年6月10日, subject to customary closing conditions. ，以惯例交割条件为前提。J. Wood Capital Advisors LLC J. Wood 资本顾问有限责任公司is acting as sole placement agent in connection with the private placement of the Notes (the “private placement”). 担任票据私募配售（“私募配售”）的唯一配售代理。Syndax estimates that the net proceeds from the private placement will be approximately Syndax估计，此次私募发行的净收益将约为$243 million 2.43亿美元, after deducting the placement agent’s fees and estimated expenses payable by Syndax. Syndax expects to use the net proceeds from the private placement for general corporate purposes, including working capital, research and development expenditures, commercialization activity expenditures and business development expenditures.. ，在扣除由Syndax支付的配售代理费用及预估开支后。Syndax预计将把私募发行的净收益用于一般企业用途，包括营运资金、研发支出、商业化活动支出以及业务发展支出。The Notes will be senior unsecured obligations of Syndax and will accrue interest payable semiannually in arrears on 该票据将为 Syndax 的高级无担保债务，并将按半年度后付方式计提并支付利息June 15 6月15日and 和December 15 12月15日of each year, beginning on 每年的，始于December 15, 2026 2026年12月15日at a rate of 2.25%. The Notes will mature on 利率为2.25%。该票据将于June 15, 2031 2031年6月15日, unless earlier converted, redeemed or repurchased. ，除非此前已转换、赎回或回购。Noteholders may convert all or any portion of their Notes at their option at any time prior to the close of business on the business day immediately preceding 票据持有人可选择在紧接前一营业日的营业结束前的任何时间，将其持有的全部或部分票据进行转换。March 15, 2031 2031年3月15日, only upon the occurrence of certain circumstances. On or after ，仅在某些情况发生时。在或之后March 15, 2031 2031年3月15日, until the close of business on the second scheduled trading day immediately preceding the maturity date, the noteholders may convert all or any portion of their Notes at any time. ，在到期日前第二个预定交易日营业结束之前，票据持有人可以随时将其持有的全部或部分票据进行转换。Upon conversion, Syndax will pay or deliver, as the case may be, cash, shares of Syndax’s common stock, par value 在转换时，Syndax 将视情况支付或交付现金、Syndax 普通股股份（面值$0.0001 $0.0001per share (the “common stock”), or a combination of cash and shares of common stock, at Syndax’s election. The conversion rate will initially be 40.3894 shares of common stock per 每股（即“普通股”），或以现金与普通股股份的组合形式，由 Syndax 自行选择。初始转换比率为每股 40.3894 股普通股$1,000 1000美元principal amount of Notes (equivalent to an initial conversion price of approximately 票据本金（相当于初始转换价格约为$24.76 24.76美元per share of common stock). The initial conversion price of the Notes represents a premium of approximately 35% over the last reported sale price of the common stock on the Nasdaq Global Select Market on 每股普通股）。票据的初始转换价格较普通股在纳斯达克全球精选市场最后报告的交易价格溢价约35%。June 3, 2026 2026年6月3日. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date of the Notes or if Syndax delivers a notice of redemption, Syndax will, in certain circumstances, increase the conversion rate for a noteholder who elects to convert its Notes in connection with such a corporate event or notice of redemption, as the case may be.. 转换率在某些情况下可能会进行调整，但不会针对应计未付利息进行调整。此外，在票据到期日之前发生某些公司事件时，或者如果 Syndax 发出赎回通知，则在特定情况下，Syndax 将提高选择在此类公司事件或赎回通知（视情况而定）相关期间转换其票据的持有人的转换率。Syndax may not redeem the Notes prior to Syndax 不得在之前赎回票据June 20, 2029 2029年6月20日. Syndax may redeem for cash all or any portion of the Notes (subject to certain limitations), at Syndax’s option, on a redemption date on or after . Syndax 可在其选择下，于一个在或之后的赎回日，以现金赎回全部或部分票据（受某些限制约束），June 20, 2029 2029年6月20日if the last reported sale price of the common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which Syndax provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.. 如果普通股的最近报告销售价格至少在连续30个交易日期间（包括该期间的最后一个交易日）的20个交易日（无论是否连续）内达到或超过当时生效的转换价格的130%，且该期间结束于并包括Syndax发出赎回通知之日的前一个交易日，赎回价格等于将被赎回票据本金金额的100%，加上截至但不包括赎回日的应计未付利息。If Syndax undergoes a “fundamental change” (as defined in the indenture that will govern the Notes), then, subject to certain conditions and limited exceptions, noteholders may require Syndax to repurchase for cash all or any portion of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.. 如果 Syndax 发生“根本性变更”（定义见将管辖该票据的契约），则在满足某些条件且受有限例外情况限制的前提下，票据持有人可要求 Syndax 以现金回购其全部或部分票据，回购价格等于拟回购票据本金金额的 100%，加上截至但不包括根本性变更回购日期的应计未付利息。Neither the Notes, nor the shares of common stock issuable upon conversion of the Notes, if any, have been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and unless so registered, may not be offered or sold in 票据及因转换票据而可发行的普通股股份（如有）均未根据经修订的《1933年证券法》（以下简称“《证券法》”）或任何州证券法律进行注册，除非已如此注册，否则不得在the United States 美国or to, or for the account or benefit of, 或向，或为……的账户或利益，U.S 美国. persons, absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws. . 人士，未进行注册或未适用《证券法》及其他适用证券法律规定的注册要求的豁免，或在不受该等注册要求约束的交易中。This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.. 本新闻稿既不构成出售任何证券的要约，也不构成购买任何证券的要约邀请，亦不在任何州或司法管辖区构成要约、邀请或销售任何证券，若在该等州或司法管辖区，未经根据当地证券法进行注册或资格认定，此类要约、邀请或销售属非法行为。AboutSyndax 关于 SyndaxSyndax Pharmaceuticalsis a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj Syndax Pharmaceuticals 是一家处于商业化阶段的生物制药公司，致力于推进创新癌症疗法。公司产品管线的亮点包括 Revuforj® ®(revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. （revumenib），一种获美国食品药品监督管理局（FDA）批准的menin抑制剂，以及Niktimvo™（axatilimab-csfr），一种获FDA批准的阻断集落刺激因子1（CSF-1）受体的单克隆抗体。在致力于重塑癌症治疗的承诺驱动下，Syndax正努力充分释放其研发管线的全部潜力，并在整个治疗过程中开展多项临床试验。For more information, please visit. 更多信息，请访问。www.syndax.com/ www.syndax.com/or follow the Company on 或在以下平台关注本公司X Xand 和LinkedIn 领英. 。Forward-Looking Statements 前瞻性陈述This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the terms of the Notes, the anticipated closing of the private placement and the anticipated use of the net proceeds from the private placement. 本新闻稿包含根据《证券法》第27A条和经修订的《1934年证券交易法》第21E条所定义的“前瞻性陈述”，涉及（包括但不限于）票据条款、预期完成的私募配售以及预期使用私募配售所得净额等事项。These forward-looking statements are based on Syndax’s current assumptions, expectations and beliefs and are subject to substantial risks, uncertainties, assumptions and changes in circumstances that may cause Syndax’s actual results, performance or achievements to differ materially from those expressed or implied in any forward-looking statement. 这些前瞻性陈述基于 Syndax 当前的假设、预期和信念，并受到重大风险、不确定性、假设及情况变化的影响，可能导致 Syndax 的实际结果、表现或成就与任何前瞻性陈述中明示或暗示的内容存在重大差异。These risks include, but are not limited to market risks, trends and conditions. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. 这些风险包括但不限于市场风险、趋势和状况。可能导致 Syndax 实际结果与本新闻稿中前瞻性陈述所表达或暗示的结果存在差异的其他因素，已在 Syndax 向美国证券交易委员会提交的文件中讨论，包括其中包含的“风险因素”部分。Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.. 除非法律另有要求，Syndax 不承担任何义务以更新本文中包含的任何前瞻性陈述，即使在新信息出现时，也不反映预期的任何变化。Syndax Contact Syndax 联系方式Sharon Klahre 莎伦·克拉赫Syndax Pharmaceuticals, Inc. Syndax 制药公司sklahre@syndax.com sklahre@syndax.comTel 781.684.9827 电话 781.684.9827SNDX-G SNDX-G

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax”) (NASDAQ: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered into privately negotiated subscription agreements for the issuance of $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (the “Notes”). The sale of the Notes is expected to close on June 10, 2026, subject to customary closing conditions. J. Wood Capital Advisors LLC is acting as sole placement agent in connection with the private placement of the Notes (the “private placement”). Syndax estimates that the net proceeds from the private placement will be approximately $243 million, after deducting the placement agent’s fees and estimated expenses payable by Syndax. Syndax expects to use the net proceeds from the private placement for general corporate purposes, including working capital, research and development expenditures, commercialization activity expenditures and business development expenditures. The Notes will be senior unsecured obligations of Syndax and will accrue interest payable semiannually in arrears on June 15 and December 15 of each year, beginning on December 15, 2026 at a rate of 2.25%. The Notes will mature on June 15, 2031, unless earlier converted, redeemed or repurchased. Noteholders may convert all or any portion of their Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2031, only upon the occurrence of certain circumstances. On or after March 15, 2031, until the close of business on the second scheduled trading day immediately preceding the maturity date, the noteholders may convert all or any portion of their Notes at any time. Upon conversion, Syndax will pay or deliver, as the case may be, cash, shares of Syndax’s common stock, par value $0.0001 per share (the “common stock”), or a combination of cash and shares of common stock, at Syndax’s election. The conversion rate will initially be 40.3894 shares of common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $24.76 per share of common stock). The initial conversion price of the Notes represents a premium of approximately 35% over the last reported sale price of the common stock on the Nasdaq Global Select Market on June 3, 2026. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date of the Notes or if Syndax delivers a notice of redemption, Syndax will, in certain circumstances, increase the conversion rate for a noteholder who elects to convert its Notes in connection with such a corporate event or notice of redemption, as the case may be. Syndax may not redeem the Notes prior to June 20, 2029. Syndax may redeem for cash all or any portion of the Notes (subject to certain limitations), at Syndax’s option, on a redemption date on or after June 20, 2029 if the last reported sale price of the common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which Syndax provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If Syndax undergoes a “fundamental change” (as defined in the indenture that will govern the Notes), then, subject to certain conditions and limited exceptions, noteholders may require Syndax to repurchase for cash all or any portion of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. Neither the Notes, nor the shares of common stock issuable upon conversion of the Notes, if any, have been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and unless so registered, may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws. This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj ® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on X and LinkedIn . Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the terms of the Notes, the anticipated closing of the private placement and the anticipated use of the net proceeds from the private placement. These forward-looking statements are based on Syndax’s current assumptions, expectations and beliefs and are subject to substantial risks, uncertainties, assumptions and changes in circumstances that may cause Syndax’s actual results, performance or achievements to differ materially from those expressed or implied in any forward-looking statement. These risks include, but are not limited to market risks, trends and conditions. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. Syndax Contact Sharon Klahre Syndax Pharmaceuticals, Inc. sklahre@syndax.com Tel 781.684.9827 SNDX-G